Pharvaris Price Target Maintained With a $55.00/Share by Citizens Capital Markets

Dow JonesMar 3 10:20 ET · Ratings

Pharvaris Reports Sustained Reduction in HAE Attack Rates and Improved Quality of Life Across Long-Term Deucrictibant Studies

Quiver QuantitativeMar 3 07:00 ET

Pharvaris Reports Safety and Efficacy Data of Deucrictibant

TipRanksMar 3 06:55 ET

Pharvaris Showcases Phase 3 Data on Deucrictibant for Hereditary Angioedema at AAAAI-WAO Congress

BenzingaMar 3 06:52 ET

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

GlobeNewswireMar 3 06:48 ET

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS) and Blueprint Medicines (BPMC)

TipRanksMar 3 00:40 ET · Ratings